Previous 10 | Next 10 |
EDMONTON, Alberta, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrolment of the first patient in a Phase I study with its partner Molecular Templates (Nasdaq: MTEM). This Phase I first-in...
Molecular Templates (NASDAQ: MTEM ): Q3 EPS of $1.03 may not be comparable to consensus of -$0.23. More news on: Molecular Templates, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s...
AUSTIN, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic the...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 125 weeks of public selections as part of this ongoing live forward-testing. In...
Shares of Molecular Templates ( MTEM ) have risen by roughly 20% since my initial recommendation last year, which highlighted its agreement with Takeda (TKPHF) to develop CD38-targeted engineered toxin bodies (ETBs). On the other hand, shares have fallen by 8% since my June update . I fel...
AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic th...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 120 weeks of public selections as part of this ongoing live forward-testing. In...
Molecular Templates (NASDAQ: MTEM ): Q2 GAAP EPS of -$0.25 misses by $0.01 . More news on: Molecular Templates, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
AUSTIN, Texas, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s...
News, Short Squeeze, Breakout and More Instantly...
Molecular Templates Inc. Company Name:
MTEM Stock Symbol:
NASDAQ Market:
Molecular Templates Inc. Website:
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineere...